Stina S.
- Country
- Norway
- Department
- Avdeling for Atferdsmedisin
Research Overview
- Randomized, Open-Label Study on Health-Related Quality of Life in Primary Adrenal Insufficiency: Comparison of Hydrocortisone (Plenadren) and Cortisone Therapy
- A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD
Data & Insights
Has run more than one trial at 2 of 180 partner sites.
Specializations
Endocrine Disorders
This investigator specializes in treating primary adrenal insufficiency (PAI), focusing on evaluating different therapeutic approaches for hormone replacement therapy. Their research encompasses the assessment of patient outcomes and quality of life with various cortisone treatment modalities.
- Adrenal Insufficiency Management
- Hormone Replacement Optimization
- Quality of Life Assessment
Metabolic Health
The investigator conducts research in the field of obesity treatment and metabolic health, with particular attention to cardiovascular outcomes in overweight patients. Their work explores innovative therapeutic approaches for weight management.
- Obesity Management
- Cardiovascular Safety
- Metabolic Disease Treatment
Cardiovascular Medicine
Their expertise extends to studying cardiovascular outcomes in metabolic conditions, including the evaluation of stroke, myocardial infarction, and heart failure events. The research focuses on assessing cardiovascular safety profiles of therapeutic interventions.
- Cardiovascular Risk Assessment
- Coronary Health Management
- Heart Failure Prevention
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.